KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Free Cash Flow (2016 - 2026)

Bio-Rad Laboratories has reported Free Cash Flow over the past 18 years, most recently at $78.1 million for Q1 2026.

  • Quarterly Free Cash Flow fell 18.22% to $78.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $357.2 million through Mar 2026, changed 0.48% year-over-year, with the annual reading at $374.6 million for FY2025, 29.35% up from the prior year.
  • Free Cash Flow was $78.1 million for Q1 2026 at Bio-Rad Laboratories, down from $119.1 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at $123.4 million in Q3 2024 and troughed at -$16.6 million in Q3 2022.
  • The 5-year median for Free Cash Flow is $62.4 million (2023), against an average of $61.3 million.
  • Year-over-year, Free Cash Flow plummeted 108.47% in 2022 and then surged 423.42% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at $44.8 million in 2022, then dropped by 13.52% to $38.7 million in 2023, then skyrocketed by 109.87% to $81.3 million in 2024, then soared by 46.49% to $119.1 million in 2025, then plummeted by 34.42% to $78.1 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Free Cash Flow are $78.1 million (Q1 2026), $119.1 million (Q4 2025), and $89.2 million (Q3 2025).